Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 55 | 2025 | 5097 | 5.570 |
Why?
|
| Cost-Benefit Analysis | 25 | 2023 | 253 | 3.820 |
Why?
|
| Anti-HIV Agents | 19 | 2023 | 1324 | 3.410 |
Why?
|
| Hypertension | 4 | 2024 | 419 | 2.510 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 139 | 2.210 |
Why?
|
| Epidemics | 5 | 2024 | 65 | 2.140 |
Why?
|
| Humans | 67 | 2025 | 14537 | 2.060 |
Why?
|
| South Africa | 50 | 2025 | 7596 | 1.980 |
Why?
|
| Pre-Exposure Prophylaxis | 7 | 2023 | 196 | 1.900 |
Why?
|
| Mass Screening | 13 | 2025 | 245 | 1.830 |
Why?
|
| Diabetes Mellitus | 2 | 2024 | 146 | 1.580 |
Why?
|
| Health Care Costs | 7 | 2022 | 115 | 1.570 |
Why?
|
| National Health Programs | 2 | 2019 | 78 | 1.200 |
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2019 | 472 | 1.170 |
Why?
|
| Sex Workers | 5 | 2022 | 116 | 1.120 |
Why?
|
| Male | 29 | 2025 | 6754 | 1.100 |
Why?
|
| Immunization Programs | 2 | 2024 | 81 | 1.090 |
Why?
|
| Female | 30 | 2025 | 9103 | 1.020 |
Why?
|
| Sexual and Gender Minorities | 2 | 2022 | 29 | 0.990 |
Why?
|
| Models, Theoretical | 9 | 2024 | 80 | 0.990 |
Why?
|
| Delivery of Health Care | 5 | 2024 | 239 | 0.890 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2023 | 3 | 0.880 |
Why?
|
| Primary Health Care | 3 | 2024 | 240 | 0.810 |
Why?
|
| Adult | 23 | 2025 | 5913 | 0.810 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 77 | 0.800 |
Why?
|
| Models, Economic | 4 | 2019 | 15 | 0.800 |
Why?
|
| Anti-Retroviral Agents | 4 | 2023 | 551 | 0.790 |
Why?
|
| Reproductive Health | 1 | 2021 | 51 | 0.750 |
Why?
|
| Medically Uninsured | 1 | 2019 | 9 | 0.670 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 237 | 0.660 |
Why?
|
| Models, Biological | 1 | 2019 | 77 | 0.650 |
Why?
|
| Adolescent | 11 | 2025 | 2985 | 0.650 |
Why?
|
| Sexual Partners | 1 | 2020 | 215 | 0.630 |
Why?
|
| Communicable Disease Control | 2 | 2022 | 101 | 0.620 |
Why?
|
| Hospitalization | 3 | 2024 | 418 | 0.620 |
Why?
|
| Topography, Medical | 1 | 2018 | 2 | 0.610 |
Why?
|
| Financing, Personal | 1 | 2017 | 12 | 0.590 |
Why?
|
| Disease Management | 1 | 2018 | 74 | 0.590 |
Why?
|
| Program Development | 1 | 2017 | 32 | 0.550 |
Why?
|
| Young Adult | 11 | 2025 | 2498 | 0.540 |
Why?
|
| Drug Costs | 3 | 2023 | 18 | 0.530 |
Why?
|
| Prevalence | 7 | 2023 | 1192 | 0.530 |
Why?
|
| Occupational Health Services | 1 | 2015 | 2 | 0.510 |
Why?
|
| Health Promotion | 1 | 2017 | 109 | 0.510 |
Why?
|
| Poverty | 3 | 2023 | 152 | 0.500 |
Why?
|
| Mining | 1 | 2015 | 41 | 0.490 |
Why?
|
| Pregnancy | 8 | 2024 | 1862 | 0.490 |
Why?
|
| Herpes Genitalis | 2 | 2014 | 43 | 0.480 |
Why?
|
| Emtricitabine | 3 | 2022 | 78 | 0.440 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 91 | 0.420 |
Why?
|
| Treatment Outcome | 8 | 2023 | 889 | 0.420 |
Why?
|
| Herpesvirus 2, Human | 2 | 2014 | 43 | 0.400 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2012 | 324 | 0.400 |
Why?
|
| Pyridones | 2 | 2023 | 100 | 0.400 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2024 | 187 | 0.390 |
Why?
|
| Circumcision, Male | 4 | 2022 | 99 | 0.380 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2012 | 59 | 0.380 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 135 | 0.380 |
Why?
|
| Acyclovir | 1 | 2011 | 11 | 0.380 |
Why?
|
| Prospective Studies | 3 | 2024 | 1160 | 0.380 |
Why?
|
| Homosexuality, Male | 2 | 2022 | 52 | 0.370 |
Why?
|
| Public Sector | 3 | 2021 | 82 | 0.370 |
Why?
|
| Rifampin | 1 | 2012 | 197 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2011 | 111 | 0.350 |
Why?
|
| Retrospective Studies | 4 | 2024 | 799 | 0.350 |
Why?
|
| Private Sector | 2 | 2021 | 45 | 0.350 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2017 | 656 | 0.340 |
Why?
|
| Middle Aged | 7 | 2025 | 3601 | 0.340 |
Why?
|
| Costs and Cost Analysis | 4 | 2020 | 42 | 0.330 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2013 | 329 | 0.330 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2009 | 33 | 0.330 |
Why?
|
| Incidence | 5 | 2023 | 685 | 0.310 |
Why?
|
| Adenine | 2 | 2022 | 91 | 0.310 |
Why?
|
| Patient Care | 2 | 2019 | 10 | 0.280 |
Why?
|
| Quality of Health Care | 2 | 2019 | 62 | 0.260 |
Why?
|
| Child | 5 | 2023 | 2242 | 0.240 |
Why?
|
| Europe, Eastern | 1 | 2024 | 3 | 0.240 |
Why?
|
| Asia, Central | 1 | 2024 | 2 | 0.240 |
Why?
|
| Transgender Persons | 1 | 2024 | 24 | 0.240 |
Why?
|
| Pandemics | 2 | 2023 | 296 | 0.230 |
Why?
|
| Health Expenditures | 1 | 2024 | 39 | 0.230 |
Why?
|
| Diketopiperazines | 1 | 2023 | 6 | 0.230 |
Why?
|
| Emigrants and Immigrants | 2 | 2017 | 11 | 0.230 |
Why?
|
| Chlamydia Infections | 1 | 2023 | 17 | 0.220 |
Why?
|
| Gonorrhea | 1 | 2023 | 20 | 0.220 |
Why?
|
| Markov Chains | 2 | 2015 | 22 | 0.220 |
Why?
|
| Tenofovir | 2 | 2022 | 171 | 0.220 |
Why?
|
| Blood Glucose | 1 | 2023 | 107 | 0.220 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 280 | 0.210 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2023 | 33 | 0.210 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 103 | 0.200 |
Why?
|
| Africa South of the Sahara | 2 | 2021 | 353 | 0.200 |
Why?
|
| Algorithms | 2 | 2013 | 106 | 0.200 |
Why?
|
| Vaccination | 1 | 2024 | 365 | 0.200 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2013 | 226 | 0.190 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 5 | 0.190 |
Why?
|
| Vulnerable Populations | 1 | 2021 | 30 | 0.190 |
Why?
|
| Alanine | 1 | 2021 | 31 | 0.190 |
Why?
|
| Risk Factors | 2 | 2023 | 1475 | 0.190 |
Why?
|
| Piperazines | 1 | 2021 | 82 | 0.190 |
Why?
|
| Oxazines | 1 | 2021 | 81 | 0.190 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 112 | 0.190 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2021 | 85 | 0.190 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 57 | 0.180 |
Why?
|
| Unsafe Sex | 1 | 2021 | 46 | 0.180 |
Why?
|
| Blood Pressure | 1 | 2023 | 317 | 0.180 |
Why?
|
| Urban Population | 2 | 2013 | 257 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2021 | 66 | 0.180 |
Why?
|
| Community Health Services | 1 | 2020 | 58 | 0.180 |
Why?
|
| General Practitioners | 1 | 2019 | 7 | 0.170 |
Why?
|
| Income | 1 | 2019 | 85 | 0.160 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 48 | 0.160 |
Why?
|
| Budgets | 1 | 2017 | 12 | 0.150 |
Why?
|
| Malawi | 3 | 2022 | 87 | 0.140 |
Why?
|
| Contraception | 1 | 2018 | 90 | 0.140 |
Why?
|
| HIV Seropositivity | 2 | 2017 | 265 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 127 | 0.140 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 115 | 0.140 |
Why?
|
| Lost to Follow-Up | 1 | 2017 | 62 | 0.140 |
Why?
|
| Risk Assessment | 1 | 2017 | 225 | 0.130 |
Why?
|
| Public Health | 1 | 2017 | 124 | 0.130 |
Why?
|
| Absenteeism | 1 | 2015 | 10 | 0.130 |
Why?
|
| Survival Rate | 1 | 2015 | 96 | 0.120 |
Why?
|
| Infant | 3 | 2023 | 2244 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2017 | 967 | 0.110 |
Why?
|
| Organophosphonates | 1 | 2014 | 45 | 0.110 |
Why?
|
| Viral Load | 2 | 2019 | 819 | 0.110 |
Why?
|
| Suburban Health Services | 1 | 2012 | 2 | 0.110 |
Why?
|
| Urban Health Services | 1 | 2012 | 10 | 0.100 |
Why?
|
| Length of Stay | 1 | 2012 | 43 | 0.100 |
Why?
|
| Diagnostic Equipment | 1 | 2012 | 3 | 0.100 |
Why?
|
| Mobile Health Units | 1 | 2012 | 7 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 472 | 0.100 |
Why?
|
| Zambia | 3 | 2021 | 115 | 0.100 |
Why?
|
| Sputum | 1 | 2012 | 135 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 529 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2013 | 1748 | 0.090 |
Why?
|
| Disease Progression | 1 | 2011 | 154 | 0.090 |
Why?
|
| Time Factors | 1 | 2012 | 507 | 0.090 |
Why?
|
| Africa, Southern | 2 | 2021 | 91 | 0.090 |
Why?
|
| Burundi | 1 | 2009 | 3 | 0.090 |
Why?
|
| Forecasting | 2 | 2023 | 20 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 106 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2009 | 54 | 0.080 |
Why?
|
| Rural Population | 1 | 2013 | 654 | 0.080 |
Why?
|
| Feasibility Studies | 2 | 2023 | 101 | 0.080 |
Why?
|
| HIV-1 | 2 | 2019 | 1260 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2012 | 543 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 1422 | 0.060 |
Why?
|
| Workplace | 1 | 2024 | 7 | 0.060 |
Why?
|
| Chlamydia trachomatis | 1 | 2023 | 13 | 0.060 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2023 | 15 | 0.060 |
Why?
|
| Standard of Care | 1 | 2023 | 30 | 0.050 |
Why?
|
| Integrases | 1 | 2023 | 2 | 0.050 |
Why?
|
| Point-of-Care Testing | 1 | 2023 | 71 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2023 | 120 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2023 | 147 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2021 | 35 | 0.050 |
Why?
|
| Health Facilities | 1 | 2021 | 40 | 0.050 |
Why?
|
| Zimbabwe | 1 | 2021 | 120 | 0.050 |
Why?
|
| Lesotho | 1 | 2020 | 6 | 0.050 |
Why?
|
| Community-Based Participatory Research | 1 | 2020 | 24 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 256 | 0.040 |
Why?
|
| Patient Selection | 1 | 2017 | 40 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2017 | 133 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 163 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 104 | 0.030 |
Why?
|
| Vietnam | 1 | 2013 | 13 | 0.030 |
Why?
|
| Eligibility Determination | 1 | 2013 | 16 | 0.030 |
Why?
|
| India | 1 | 2013 | 62 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 34 | 0.030 |
Why?
|
| Medical Laboratory Science | 1 | 2013 | 4 | 0.030 |
Why?
|
| Outpatients | 1 | 2013 | 38 | 0.030 |
Why?
|
| Geography | 1 | 2012 | 60 | 0.030 |
Why?
|
| Demography | 1 | 2012 | 105 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2012 | 48 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2013 | 167 | 0.020 |
Why?
|
| Medical Audit | 1 | 2009 | 26 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2009 | 125 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2013 | 1479 | 0.020 |
Why?
|